Showing 2481-2490 of 2705 results for "".
- Revance Enters Exclusive Distribution Deal with Teoxane SA for Dermal Fillershttps://modernaesthetics.com/news/revance-enters-exclusive-distribution-deal-with-teoxane-sa-for-dermal-fillers/2472863/With the signing of a new distribution agreement, Revance Therapeutics, Inc. is now the exclusive US commercialization partner of Teoxane SA for its dermal filler products. Revance has immediate and exclusive rights to commercialize Teoxane’s Resilient Hyaluronic Acid® (R
- Lutronic Introduces the Most Powerful Thulium Laser to Receive FDA Clearancehttps://modernaesthetics.com/news/lutronic-introduces-the-most-powerful-thulium-laser-to-receive-fda-clearance/2472852/Lutronic unveiled the new LaseMD ULTRA™ during live patient demonstrations at the Cosmetic Surgery Forum in Nashville, TN. The LaseMD ULTRA offersthe highest available power that allows for fast treatments, customizable for multiple areas. Additionally, the system providesgen
- ISAPS: Brazil, US Remain Cosmetic Surgery Capitals of the Worldhttps://modernaesthetics.com/news/isaps-brazil-us-remain-cosmetic-surgery-capitals-of-the-world/2472850/Driven by increases in non-invasive procedures, plastic surgery across the globe is on the rise, according to the annual statistics from the International Society of Aesthetic Plastic Surgery (ISAPS), and the US and Brazil remain the cosmetic surgery capitals o
- Revance's DAXI Now One Step Closer to FDA Nodhttps://modernaesthetics.com/news/revances-daxi-now-one-step-closer-to-fda-nod/2472849/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under
- Business News: Hologic to Offload Cynosure for $205Mhttps://modernaesthetics.com/news/business-news-hologic-to-offload-cynosure-for-205m/2472847/Hologic is selling Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, subject to certain closing adjustments. This is a tenth of the $1.6B that Hologic, a women
- Kylie Jenner Sells Majority Stake in Beauty Business to Cotyhttps://modernaesthetics.com/news/kylie-jenner-sells-majority-stake-in-beauty-business-to-coty/2472846/Kylie Jenner sold a $600M majority stake in Kylie Cosmetics and Kylie Skin to Coty Inc. Under the terms of the agreement, Coty will acquire a 51 percent ownership in the partnership for $600M. The acquisition is expected to close in the third quarter of fiscal year 2020. Coty's
- Venus Concept Completes Merger with Restoration Roboticshttps://modernaesthetics.com/news/venus-concept-completes-merger-with-restoration-robotics/2472842/Venus Concept Inc. has completed its previously announced merger with Restoration Robotic, Inc., effective November 7, 2019. Following the completion of the merger, Venus Concept completed a $28 million equity financing by EW Health
- Update: Instagram Removes Cosmetic Surgery Filtershttps://modernaesthetics.com/news/update-instagram-removes-cosmetic-surgery-filters/2472841/In a move designed to promote mental well being, Instagram, owned by Facebook, is removing all augmented reality filters that depict cosmetic surgery. In addition, the social media giant is striking all effects from the gallery that are associated with plastic surgery and postponing the
- Cynosure Rolls Out StimSure for Muscle Toning in Europe, Middle Easthttps://modernaesthetics.com/news/cynosure-rolls-out-stimsure-for-muscle-toning-in-europe-middle-east/2472839/Cynosure, a division of Hologic, is launching StimSure, a non-invasive electromagnetic technology to build and tone muscle in the abdomen, buttocks and thighs, in Europe and the Middle East. CE marked for muscular atrophy, StimSure can be used to strengthen and tighten the abdomina
- Galderma Set to Start Seven New Clinical Studieshttps://modernaesthetics.com/news/galderma-set-to-start-begin-seven-new-clinical-studies/2472838/Galderma is initiating seven clinical studies that seek to support potential, new aesthetic indications including a tear trough indication for Restylane, a facial wrinkles indication for Sculptra Aesthetic as well as several studies supporting an investigational liquid neurotoxin and a Phase 2 st